A Phase 3 interventional study of Alirocumab and Atorvastatin in Hypercholesterolemia, sponsored by Regeneron Pharmaceuticals. Completed at 97 sites in 9 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2015-08-31.
Sponsored by Regeneron Pharmaceuticals · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 43 studies testing alirocumab in Hypercholesterolemia — 1 open to participants now, 2 under way, none of them phase 3. alirocumab · Hypercholesterolemia.
Among the 43 studies testing alirocumab in Hypercholesterolemia, this one is the 12th largest by enrollment, is one of 12 that started in 2012, is one of 20 in phase 3, and was the 19th registered.
1,177 studies on the registry are indexed under Hypercholesterolemia; 95 are open to participants now.
Browse Hypercholesterolemia studies →1 of the 43 studies testing alirocumab in Hypercholesterolemia is open now, in 1 country. Recruiting first, the newest first:
University Medical Centre Ljubljana · Sites in Slovenia
Ages 18+
By country, each count listing its studies:
alirocumab: first FDA approval 2015 (PRALUENT), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →
Of the 55 Hypercholesterolemia studies recruiting now, 23 (42%) set no upper age limit and 20 (36%) stop at 75 or younger; 9 take children under 18; 11 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
43 studies; the count open now beside each. This study's row is marked.
First in 2010; this study’s year is marked. 12 started in 2012.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 355 is above the median of 110 across 976 interventional studies indexed under Hypercholesterolemia.
Median enrollment 107 across the 43 interventional studies. Of the 40 that completed or were terminated, 30 (75%) have results posted.
This tab as a report to print or save as PDF → With an account.
39 of 43 have an industry lead sponsor. The 6 most frequent:
Regeneron Pharmaceuticals is the lead sponsor of 412 studies on the registry; 90 are open to participants now.
Of its 126 completed or terminated interventional studies of FDA-regulated products, 79 (63%) have results posted.
13 studies in Hypercholesterolemia by Regeneron Pharmaceuticals: none open now, 1 under way, none of them phase 3. Of 12 finished, 10 (83%) have results posted.
Among the 13 studies in Hypercholesterolemia by Regeneron Pharmaceuticals, this one is the 5th largest by enrollment of the 12 interventional ones that give a count, is one of 5 that started in 2012, is one of 4 in phase 3, and was the 6th registered.
Regeneron Pharmaceuticals’s Hypercholesterolemia studies by the year they started, since 2010.
2 of the studies testing alirocumab in Hypercholesterolemia that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07477704Regeneron PharmaceuticalsA Study to See How Safe and Effective Alirocumab is When Given Weekly to Adult Participants Who Have Hypercholesterolemia | 2026-12-29 |
| NCT07581808University Medical Centre LjubljanaDual PCSK9 Inhibition With Inclisiran and Alirocumab in Secondary Prevention | 2027-05 |
Add all 2 to your calendar (.ics) → With an account.
Among the 43 studies testing alirocumab in Hypercholesterolemia, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Regeneron Pharmaceuticals’s 13 in Hypercholesterolemia:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This is a randomized, double-blind, active-comparator, parallel-group study in patients at high cardiovascular risk with nonfamilial hypercholesterolemia or heterozygous familial hypercholesterolemia (heFH).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
(The inclusion/ exclusion criteria provided above is not intended to contain all considerations relevant to a patient's potential participation in this clinical trial).
Participants, who were receiving atorvastatin 20 mg over-encapsulated tablets orally at baseline, received atorvastatin 40 mg over-encapsulated tablets orally once daily (QD), placebo for alirocumab SC injection every two weeks (Q2W), and placebo for ezetimibe over-encapsulated tablets orally QD added to stable Lipid-Modifying Therapy (LMT) for 24 weeks.
Drug: Atorvastatin · Drug: Placebo
Participants, who were receiving atorvastatin 20 mg over-encapsulated tablets orally at baseline, received ezetimibe 10 mg over-encapsulated tablets orally QD, atorvastatin 20 mg over-encapsulated tablets orally QD, and placebo for alirocumab SC injection Q2W added to stable LMT for 24 weeks.
Drug: Atorvastatin · Drug: Ezetimibe · Drug: Placebo
Participants, who were receiving atorvastatin 20 mg over-encapsulated tablets orally at baseline, received Alirocumab 75 mg SC injection Q2W, atorvastatin 20 mg over-encapsulated tablets orally QD, and placebo for ezetimibe over-encapsulated tablets orally QD added to stable LMT for 24 weeks. Alirocumab dose up-titrated to 150 mg Q2W from Week 12 when LDL-C levels ≥70 mg/dL (1.81 mmol/L) or ≥100 mg/dL (2.59 mmol/L) at Week 8, based on baseline disease characteristic and medical history.
Drug: Alirocumab · Drug: Atorvastatin · Drug: Placebo
Participants, who were receiving atorvastatin 40 mg over-encapsulated tablets orally at baseline, received Atorvastatin 80 mg over-encapsulated tablets orally QD, placebo for alirocumab SC injection Q2W, and placebo for ezetimibe over-encapsulated tablets orally QD added to stable LMT for 24 weeks.
Drug: Atorvastatin · Drug: Placebo
Participants, who were receiving atorvastatin 40 mg over-encapsulated tablets orally at baseline, received rosuvastatin 40 mg over-encapsulated tablets orally QD, placebo for alirocumab SC injection Q2W, and placebo for ezetimibe over-encapsulated tablets orally QD added to stable LMT for 24 weeks.
Drug: Rosuvastatin · Drug: Placebo
Participants, who were receiving atorvastatin 40 mg over-encapsulated tablets orally at baseline, received ezetimibe 10 mg over-encapsulated tablets orally QD, atorvastatin 40 mg over-encapsulated tablets orally QD, and placebo for alirocumab SC injection Q2W added to stable LMT for 24 weeks.
Drug: Atorvastatin · Drug: Ezetimibe · Drug: Placebo
Participants, who were receiving atorvastatin 40 mg over-encapsulated tablets orally at baseline, received alirocumab 75 mg SC injection Q2W, atorvastatin 40 mg over-encapsulated tablets orally QD, and placebo for ezetimibe over-encapsulated tablets orally QD added to stable LMT for 24 weeks. Alirocumab dose up-titrated to 150 mg Q2W from Week 12 when LDL-C levels ≥70 mg/dL (1.81 mmol/L) or ≥100 mg/dL (2.59 mmol/L) at Week 8, based on baseline disease characteristic and medical history.
Drug: Alirocumab · Drug: Atorvastatin · Drug: Placebo
Alirocumab administered as a SC injection of 1 mL into the abdomen, thigh, or outer area of the upper arm.
Also known as: REGN727/SAR236553
Atorvastatin over-encapsulated tablets orally.
Ezetimibe over-encapsulated tablet orally.
Also known as: Ezetrol
Rosuvastatin over-encapsulated tablets orally.
Also known as: Crestor
Placebo for alirocumab and ezetimibe.
Percent Change From Baseline in Calculated LDL-C at Week 24 - Intent-to-treat (ITT) Analysis
Calculated LDL-C values were obtained from Friedewald formula. Adjusted Least-squares (LS) means and standard errors at Week 24 were obtained from a mixed-effect model with repeated measures (MMRM) to account for missing data. All available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment were used in the model (ITT analysis).
Time frame: From Baseline to Week 24
Percent Change From Baseline in Calculated LDL-C at Week 24 - On-Treatment Analysis
Calculated LDL-C values were obtained from Friedewald formula. Adjusted LS means and standard errors at Week 24 were obtained from MMRM model including available post-baseline on-treatment data from Week 4 to Week 24 (i.e. up to 21 days after last injection or 3 days after the last capsule \[whatever atorvastatin, rosuvastatin or ezetimibe\], whichever came first) (on-treatment analysis).
Time frame: From Baseline to Week 24
Percent Change From Baseline in Calculated LDL-C at Week 12 - ITT Analysis
Calculated LDL-C values were obtained from Friedewald formula. Adjusted LS means and standard errors at Week 12 from MMRM model including all available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment (ITT analysis).
Time frame: From Baseline to Week 24
Percent Change From Baseline in Calculated LDL-C at Week 12 - On-Treatment Analysis
Calculated LDL-C values were obtained from Friedewald formula. Adjusted LS means and standard errors at Week 12 were obtained from MMRM model including available post-baseline on-treatment data from Week 4 to Week 24 (i.e. up to 21 days after last injection or 3 days after the last capsule \[whatever atorvastatin, rosuvastatin or ezetimibe\], whichever came first) (on-treatment analysis).
Time frame: From Baseline to Week 24
Percent Change From Baseline in Apolipoprotein (Apo) B at Week 24 - ITT Analysis
Adjusted LS means and standard errors at Week 24 from MMRM model including all available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment.
Time frame: From Baseline to Week 24
Percent Change From Baseline in Apo B at Week 24 - On-Treatment Analysis
Adjusted LS means and standard errors at Week 24 were obtained from MMRM model including available post-baseline on-treatment data from Week 4 to Week 24 (ie. up to 21 days after last injection or 3 days after the last capsule \[whatever atorvastatin, rosuvastatin or ezetimibe\], whichever came first).
Time frame: From Baseline to Week 24
Percent Change From Baseline in Non-High-density Lipoprotein Cholesterol (Non-HDL-C) at Week 24 - ITT Analysis
Adjusted LS means and standard errors at Week 24 from MMRM model including all available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment.
Time frame: From Baseline to Week 24
Percent Change From Baseline in Non-HDL-C at Week 24 - On-Treatment Analysis
Adjusted LS means and standard errors at Week 24 were obtained from MMRM model including available post-baseline on-treatment data from Week 4 to Week 24 (i.e. up to 21 days after last injection or 3 days after the last capsule \[whatever atorvastatin, rosuvastatin or ezetimibe\], whichever came first).
Time frame: From Baseline to Week 24
Percent Change From Baseline in Total Cholesterol (Total-C) at Week 24 - ITT Analysis
Adjusted LS means and standard errors at Week 24 from MMRM model including all available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment.
Time frame: From Baseline to Week 24
Percent Change From Baseline in Apo B at Week 12 - ITT Analysis
Adjusted LS means and standard errors at Week 12 from MMRM model including all available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment.
Time frame: From Baseline to Week 24
Percent Change From Baseline in Non-HDL-C at Week 12 - ITT Analysis
Adjusted LS means and standard errors at Week 12 from MMRM model including all available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment.
Time frame: From Baseline to Week 24
Percent Change From Baseline in Total-C at Week 12 - ITT Analysis
Adjusted LS means and standard errors at Week 12 from MMRM model including all available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment.
Time frame: From Baseline to Week 24
Percentage of Very High CV Risk Participants Reaching Calculated LDL-C <70 mg/dL (1.81 mmol/L) or High CV Risk Participants Reaching Calculated LDL-C <100 mg/dL (2.59 mmol/L) at Week 24 - ITT Analysis
Adjusted percentages at Week 24 were obtained from a multiple imputation approach model for handling of missing data. All available post-baseline data from Week 4 to week 24 regardless of status on- or off-treatment were included in the imputation model (ITT analysis).
Time frame: Up to Week 24
Percentage of Very High CV Risk Participants Reaching Calculated LDL-C <70 mg/dL (1.81 mmol/L) or High CV Risk Participants Reaching Calculated LDL-C <100 mg/dL (2.59 mmol/L) at Week 24 - On-Treatment Analysis
Adjusted percentages at Week 24 were obtained from a multiple imputation approach model including available post-baseline on-treatment data from Week 4 to Week 24 i.e. up to 21 days after last injection or 3 days after the last capsule \[whatever atorvastatin, rosuvastatin or ezetimibe\], whichever came first (on-treatment analysis).
Time frame: Up to Week 24
Percentage of Participants Reaching Calculated LDL-C <70 mg/dL (1.81 mmol/L) at Week 24 - ITT Analysis
Adjusted percentages at Week 24 were obtained from a multiple imputation approach model for handling of missing data. All available post-baseline data from Week 4 to week 24 regardless of status on- or off-treatment were included in the imputation model (ITT analysis).
Time frame: Up to Week 24
Percentage of Participants Reaching Calculated LDL-C <70 mg/dL (1.81 mmol/L) at Week 24 - On-Treatment Analysis
Adjusted percentages at Week 24 were obtained from a multiple imputation approach model including available post-baseline on-treatment data from Week 4 to Week 24 i.e. up to 21 days after last injection or 3 days after the last capsule \[whatever atorvastatin, rosuvastatin or ezetimibe\], whichever came first (on-treatment analysis).
Time frame: Up to Week 24
Percent Change From Baseline in Lipoprotein(a) at Week 24 - ITT Analysis
Adjusted means and standard errors at Week 24 from from a multiple imputation approach model including all available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment.
Time frame: From Baseline to Week 24
Percent Change From Baseline in HDL-C at Week 24 - ITT Analysis
Adjusted LS means and standard errors at Week 24 from MMRM model including all available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment.
Time frame: From Baseline to Week 24
Percent Change From Baseline in Fasting Triglycerides at Week 24 - ITT Analysis
Adjusted means and standard errors at Week 24 from from a multiple imputation approach model including all available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment.
Time frame: From Baseline to Week 24
Percent Change From Baseline in Apo A-1 at Week 24 - ITT Analysis
Adjusted LS means and standard errors at Week 24 from MMRM model including all available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment.
Time frame: From Baseline to Week 24
Percent Change From Baseline in Lipoprotein(a) at Week 12 - ITT Analysis
Adjusted means and standard errors at Week 12 from from a multiple imputation approach model including all available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment.
Time frame: From Baseline to Week 24
Percent Change From Baseline in HDL-C at Week 12 - ITT Analysis
Adjusted LS means and standard errors at Week 12 from MMRM model including all available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment.
Time frame: From Baseline to Week 24
Percent Change From Baseline in Fasting Triglycerides at Week 12 - ITT Analysis
Adjusted means and standard errors at Week 12 from from a multiple imputation approach model including all available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment.
Time frame: From Baseline to Week 24
Percent Change From Baseline in Apo A-1 at Week 12 - ITT Analysis
Adjusted LS means and standard errors at Week 12 from MMRM model including all available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment.
Time frame: From Baseline to Week 24
The study was conducted at 85 sites in 9 countries. Overall, 859 subjects were screened between 24 October 2012 and 26 September 2013, 504 of whom were screen failures. Screen failures ware mainly due to exclusion criteria met.
| Milestone | Atorvastatin 40 mg | Ezetimibe 10 mg + Atorvastatin 20 mg | Alirocumab 75 mg/up to 150 mg + Atorvastatin 20 mg | Atorvastatin 80 mg | Rosuvastatin 40 mg | Ezetimibe 10 mg + Atorvastatin 40 mg | Alirocumab 75 mg/up to 150 mg + Atorvastatin 40 mg |
|---|---|---|---|---|---|---|---|
| Started | 57 | 55 | 57 | 47 | 45 | 47 | 47 |
| Treated | 57 | 55 | 57 | 47 | 45 | 46 | 47 |
| Completed | 44 | 40 | 46 | 39 | 39 | 40 | 38 |
| Not completed | 13 | 15 | 11 | 8 | 6 | 7 | 9 |
| Withdrew: Randomized but not treated | 0 | 0 | 0 | 0 | 0 | 1 | 0 |
| Withdrew: Subject moved | 0 | 0 | 1 | 0 | 0 | 0 | 1 |
| Withdrew: Physician decision | 0 | 0 | 0 | 0 | 0 | 1 | 1 |
| Withdrew: Other than specified | 7 | 8 | 5 | 5 | 5 | 4 | 4 |
| Withdrew: Adverse event | 4 | 3 | 5 | 3 | 1 | 1 | 2 |
| Withdrew: Poor compliance to protocol | 2 | 4 | 0 | 0 | 0 | 0 | 1 |
Calculated LDL-C values were obtained from Friedewald formula. Adjusted Least-squares (LS) means and standard errors at Week 24 were obtained from a mixed-effect model with repeated measures (MMRM) to account for missing data. All available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment were used in the model (ITT analysis).
| percent change | Atorvastatin 40 mg | Ezetimibe 10 mg + Atorvastatin 20 mg | Alirocumab 75 mg/up to 150 mg + Atorvastatin 20 mg | Atorvastatin 80 mg | Rosuvastatin 40 mg | Ezetimibe 10 mg + Atorvastatin 40 mg | Alirocumab 75 mg/up to 150 mg + Atorvastatin 40 mg |
|---|---|---|---|---|---|---|---|
| Percent Change From Baseline in Calculated LDL-C at Week 24 - Intent-to-treat (ITT) Analysis | -5 ± 4.6 | -20.5 ± 4.7 | -44.1 ± 4.5 | -4.8 ± 4.2 | -21.4 ± 4.2 | -22.6 ± 4.3 | -54 ± 4.3 |
Calculated LDL-C values were obtained from Friedewald formula. Adjusted LS means and standard errors at Week 24 were obtained from MMRM model including available post-baseline on-treatment data from Week 4 to Week 24 (i.e. up to 21 days after last injection or 3 days after the last capsule \[whatever atorvastatin, rosuvastatin or ezetimibe\], whichever came first) (on-treatment analysis).
| percent change | Atorvastatin 40 mg | Ezetimibe 10 mg + Atorvastatin 20 mg | Alirocumab 75 mg/up to 150 mg + Atorvastatin 20 mg | Atorvastatin 80 mg | Rosuvastatin 40 mg | Ezetimibe 10 mg + Atorvastatin 40 mg | Alirocumab 75 mg/up to 150 mg + Atorvastatin 40 mg |
|---|---|---|---|---|---|---|---|
| Percent Change From Baseline in Calculated LDL-C at Week 24 - On-Treatment Analysis | -6.1 ± 4.6 | -23.7 ± 4.7 | -48.6 ± 4.5 | -5.0 ± 4.4 | -22.9 ± 4.4 | -24.5 ± 4.5 | -57.8 ± 4.5 |
Calculated LDL-C values were obtained from Friedewald formula. Adjusted LS means and standard errors at Week 12 from MMRM model including all available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment (ITT analysis).
| percent change | Atorvastatin 40 mg | Ezetimibe 10 mg + Atorvastatin 20 mg | Alirocumab 75 mg/up to 150 mg + Atorvastatin 20 mg | Atorvastatin 80 mg | Rosuvastatin 40 mg | Ezetimibe 10 mg + Atorvastatin 40 mg | Alirocumab 75 mg/up to 150 mg + Atorvastatin 40 mg |
|---|---|---|---|---|---|---|---|
| Percent Change From Baseline in Calculated LDL-C at Week 12 - ITT Analysis | -8.5 ± 3.9 | -22.6 ± 3.9 | -48.4 ± 3.8 | -14.5 ± 3.2 | -23.3 ± 3.2 | -29.7 ± 3.2 | -50.5 ± 3.2 |
Calculated LDL-C values were obtained from Friedewald formula. Adjusted LS means and standard errors at Week 12 were obtained from MMRM model including available post-baseline on-treatment data from Week 4 to Week 24 (i.e. up to 21 days after last injection or 3 days after the last capsule \[whatever atorvastatin, rosuvastatin or ezetimibe\], whichever came first) (on-treatment analysis).
| percent change | Atorvastatin 40 mg | Ezetimibe 10 mg + Atorvastatin 20 mg | Alirocumab 75 mg/up to 150 mg + Atorvastatin 20 mg | Atorvastatin 80 mg | Rosuvastatin 40 mg | Ezetimibe 10 mg + Atorvastatin 40 mg | Alirocumab 75 mg/up to 150 mg + Atorvastatin 40 mg |
|---|---|---|---|---|---|---|---|
| Percent Change From Baseline in Calculated LDL-C at Week 12 - On-Treatment Analysis | -9.2 ± 3.1 | -27.1 ± 3.1 | -53.7 ± 3.1 | -14.6 ± 3.2 | -23.3 ± 3.2 | -30.7 ± 3.2 | -50.9 ± 3.2 |
Adjusted LS means and standard errors at Week 24 from MMRM model including all available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment.
| percent change | Atorvastatin 40 mg | Ezetimibe 10 mg + Atorvastatin 20 mg | Alirocumab 75 mg/up to 150 mg + Atorvastatin 20 mg | Atorvastatin 80 mg | Rosuvastatin 40 mg | Ezetimibe 10 mg + Atorvastatin 40 mg | Alirocumab 75 mg/up to 150 mg + Atorvastatin 40 mg |
|---|---|---|---|---|---|---|---|
| Percent Change From Baseline in Apolipoprotein (Apo) B at Week 24 - ITT Analysis | -4.4 ± 3.5 | -10.1 ± 3.6 | -33.7 ± 3.4 | -3.5 ± 3.3 | -10.9 ± 3.2 | -14.3 ± 3.3 | -41.9 ± 3.4 |
Adjusted LS means and standard errors at Week 24 were obtained from MMRM model including available post-baseline on-treatment data from Week 4 to Week 24 (ie. up to 21 days after last injection or 3 days after the last capsule \[whatever atorvastatin, rosuvastatin or ezetimibe\], whichever came first).
| percent change | Atorvastatin 40 mg | Ezetimibe 10 mg + Atorvastatin 20 mg | Alirocumab 75 mg/up to 150 mg + Atorvastatin 20 mg | Atorvastatin 80 mg | Rosuvastatin 40 mg | Ezetimibe 10 mg + Atorvastatin 40 mg | Alirocumab 75 mg/up to 150 mg + Atorvastatin 40 mg |
|---|---|---|---|---|---|---|---|
| Percent Change From Baseline in Apo B at Week 24 - On-Treatment Analysis | -5.1 ± 3.3 | -12.6 ± 3.5 | -37.7 ± 3.2 | -4.4 ± 3.4 | -12.8 ± 3.4 | -16.3 ± 3.4 | -42.7 ± 3.5 |
Adjusted LS means and standard errors at Week 24 from MMRM model including all available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment.
| percent change | Atorvastatin 40 mg | Ezetimibe 10 mg + Atorvastatin 20 mg | Alirocumab 75 mg/up to 150 mg + Atorvastatin 20 mg | Atorvastatin 80 mg | Rosuvastatin 40 mg | Ezetimibe 10 mg + Atorvastatin 40 mg | Alirocumab 75 mg/up to 150 mg + Atorvastatin 40 mg |
|---|---|---|---|---|---|---|---|
| Percent Change From Baseline in Non-High-density Lipoprotein Cholesterol (Non-HDL-C) at Week 24 - ITT Analysis | -6.3 ± 3.9 | -15.1 ± 4.0 | -36.7 ± 3.9 | -6.5 ± 3.6 | -17.4 ± 3.6 | -21.0 ± 3.7 | -47.6 ± 3.7 |
Adjusted LS means and standard errors at Week 24 were obtained from MMRM model including available post-baseline on-treatment data from Week 4 to Week 24 (i.e. up to 21 days after last injection or 3 days after the last capsule \[whatever atorvastatin, rosuvastatin or ezetimibe\], whichever came first).
| percent change | Atorvastatin 40 mg | Ezetimibe 10 mg + Atorvastatin 20 mg | Alirocumab 75 mg/up to 150 mg + Atorvastatin 20 mg | Atorvastatin 80 mg | Rosuvastatin 40 mg | Ezetimibe 10 mg + Atorvastatin 40 mg | Alirocumab 75 mg/up to 150 mg + Atorvastatin 40 mg |
|---|---|---|---|---|---|---|---|
| Percent Change From Baseline in Non-HDL-C at Week 24 - On-Treatment Analysis | -7.5 ± 3.8 | -18.1 ± 4.0 | -40.5 ± 3.7 | -7.0 ± 3.7 | -18.4 ± 3.7 | -23.3 ± 3.8 | -50.5 ± 3.8 |
Adjusted LS means and standard errors at Week 24 from MMRM model including all available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment.
| percent change | Atorvastatin 40 mg | Ezetimibe 10 mg + Atorvastatin 20 mg | Alirocumab 75 mg/up to 150 mg + Atorvastatin 20 mg | Atorvastatin 80 mg | Rosuvastatin 40 mg | Ezetimibe 10 mg + Atorvastatin 40 mg | Alirocumab 75 mg/up to 150 mg + Atorvastatin 40 mg |
|---|---|---|---|---|---|---|---|
| Percent Change From Baseline in Total Cholesterol (Total-C) at Week 24 - ITT Analysis | -4.0 ± 2.7 | -11.2 ± 2.8 | -27.1 ± 2.7 | -4.8 ± 2.8 | -11.7 ± 2.8 | -15.2 ± 2.9 | -33.6 ± 2.9 |
Adjusted LS means and standard errors at Week 12 from MMRM model including all available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment.
| percent change | Atorvastatin 40 mg | Ezetimibe 10 mg + Atorvastatin 20 mg | Alirocumab 75 mg/up to 150 mg + Atorvastatin 20 mg | Atorvastatin 80 mg | Rosuvastatin 40 mg | Ezetimibe 10 mg + Atorvastatin 40 mg | Alirocumab 75 mg/up to 150 mg + Atorvastatin 40 mg |
|---|---|---|---|---|---|---|---|
| Percent Change From Baseline in Apo B at Week 12 - ITT Analysis | -6.9 ± 2.8 | -13.1 ± 2.8 | -38.4 ± 2.7 | -9.5 ± 2.5 | -14.1 ± 2.5 | -20.3 ± 2.5 | -36.2 ± 2.5 |
Adjusted LS means and standard errors at Week 12 from MMRM model including all available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment.
| percent change | Atorvastatin 40 mg | Ezetimibe 10 mg + Atorvastatin 20 mg | Alirocumab 75 mg/up to 150 mg + Atorvastatin 20 mg | Atorvastatin 80 mg | Rosuvastatin 40 mg | Ezetimibe 10 mg + Atorvastatin 40 mg | Alirocumab 75 mg/up to 150 mg + Atorvastatin 40 mg |
|---|---|---|---|---|---|---|---|
| Percent Change From Baseline in Non-HDL-C at Week 12 - ITT Analysis | -7.1 ± 3.2 | -17.2 ± 3.2 | -40.6 ± 3.2 | -13.0 ± 2.6 | -19.8 ± 2.7 | -27.5 ± 2.7 | -42.3 ± 2.7 |
Adjusted LS means and standard errors at Week 12 from MMRM model including all available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment.
| percent change | Atorvastatin 40 mg | Ezetimibe 10 mg + Atorvastatin 20 mg | Alirocumab 75 mg/up to 150 mg + Atorvastatin 20 mg | Atorvastatin 80 mg | Rosuvastatin 40 mg | Ezetimibe 10 mg + Atorvastatin 40 mg | Alirocumab 75 mg/up to 150 mg + Atorvastatin 40 mg |
|---|---|---|---|---|---|---|---|
| Percent Change From Baseline in Total-C at Week 12 - ITT Analysis | -6.5 ± 2.4 | -13.2 ± 2.4 | -29.0 ± 2.4 | -9.9 ± 2.1 | -13.5 ± 2.1 | -19.2 ± 2.1 | -29.0 ± 2.1 |
Adjusted percentages at Week 24 were obtained from a multiple imputation approach model for handling of missing data. All available post-baseline data from Week 4 to week 24 regardless of status on- or off-treatment were included in the imputation model (ITT analysis).
| percentage of participants | Atorvastatin 40 mg | Ezetimibe 10 mg + Atorvastatin 20 mg | Alirocumab 75 mg/up to 150 mg + Atorvastatin 20 mg | Atorvastatin 80 mg | Rosuvastatin 40 mg | Ezetimibe 10 mg + Atorvastatin 40 mg | Alirocumab 75 mg/up to 150 mg + Atorvastatin 40 mg |
|---|---|---|---|---|---|---|---|
| Percentage of Very High CV Risk Participants Reaching Calculated LDL-C <70 mg/dL (1.81 mmol/L) or High CV Risk Participants Reaching Calculated LDL-C <100 mg/dL (2.59 mmol/L) at Week 24 - ITT Analysis | 34.5 | 68.4 | 87.2 | 18.5 | 62.2 | 65.1 | 84.6 |
Adjusted percentages at Week 24 were obtained from a multiple imputation approach model including available post-baseline on-treatment data from Week 4 to Week 24 i.e. up to 21 days after last injection or 3 days after the last capsule \[whatever atorvastatin, rosuvastatin or ezetimibe\], whichever came first (on-treatment analysis).
| percentage of participants | Atorvastatin 40 mg | Ezetimibe 10 mg + Atorvastatin 20 mg | Alirocumab 75 mg/up to 150 mg + Atorvastatin 20 mg | Atorvastatin 80 mg | Rosuvastatin 40 mg | Ezetimibe 10 mg + Atorvastatin 40 mg | Alirocumab 75 mg/up to 150 mg + Atorvastatin 40 mg |
|---|---|---|---|---|---|---|---|
| Percentage of Very High CV Risk Participants Reaching Calculated LDL-C <70 mg/dL (1.81 mmol/L) or High CV Risk Participants Reaching Calculated LDL-C <100 mg/dL (2.59 mmol/L) at Week 24 - On-Treatment Analysis | 37.8 | 72.2 | 91.2 | 18.5 | 64.0 | 66.2 | 90.0 |
Adjusted percentages at Week 24 were obtained from a multiple imputation approach model for handling of missing data. All available post-baseline data from Week 4 to week 24 regardless of status on- or off-treatment were included in the imputation model (ITT analysis).
| percentage of participants | Atorvastatin 40 mg | Ezetimibe 10 mg + Atorvastatin 20 mg | Alirocumab 75 mg/up to 150 mg + Atorvastatin 20 mg | Atorvastatin 80 mg | Rosuvastatin 40 mg | Ezetimibe 10 mg + Atorvastatin 40 mg | Alirocumab 75 mg/up to 150 mg + Atorvastatin 40 mg |
|---|---|---|---|---|---|---|---|
| Percentage of Participants Reaching Calculated LDL-C <70 mg/dL (1.81 mmol/L) at Week 24 - ITT Analysis | 16.0 | 50.3 | 79.2 | 10.2 | 42.2 | 54.2 | 77.2 |
Adjusted percentages at Week 24 were obtained from a multiple imputation approach model including available post-baseline on-treatment data from Week 4 to Week 24 i.e. up to 21 days after last injection or 3 days after the last capsule \[whatever atorvastatin, rosuvastatin or ezetimibe\], whichever came first (on-treatment analysis).
| percentage of participants | Atorvastatin 40 mg | Ezetimibe 10 mg + Atorvastatin 20 mg | Alirocumab 75 mg/up to 150 mg + Atorvastatin 20 mg | Atorvastatin 80 mg | Rosuvastatin 40 mg | Ezetimibe 10 mg + Atorvastatin 40 mg | Alirocumab 75 mg/up to 150 mg + Atorvastatin 40 mg |
|---|---|---|---|---|---|---|---|
| Percentage of Participants Reaching Calculated LDL-C <70 mg/dL (1.81 mmol/L) at Week 24 - On-Treatment Analysis | 20.0 | 55.1 | 82.3 | 10.5 | 42.4 | 55.3 | 83.7 |
Adjusted means and standard errors at Week 24 from from a multiple imputation approach model including all available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment.
| percent change | Atorvastatin 40 mg | Ezetimibe 10 mg + Atorvastatin 20 mg | Alirocumab 75 mg/up to 150 mg + Atorvastatin 20 mg | Atorvastatin 80 mg | Rosuvastatin 40 mg | Ezetimibe 10 mg + Atorvastatin 40 mg | Alirocumab 75 mg/up to 150 mg + Atorvastatin 40 mg |
|---|---|---|---|---|---|---|---|
| Percent Change From Baseline in Lipoprotein(a) at Week 24 - ITT Analysis | -20.2 ± 4.0 | -10.6 ± 4.4 | -23.6 ± 4.0 | -9.7 ± 4.1 | -4.9 ± 3.7 | 0.2 ± 3.9 | -30.8 ± 4.1 |
Adjusted LS means and standard errors at Week 24 from MMRM model including all available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment.
| percent change | Atorvastatin 40 mg | Ezetimibe 10 mg + Atorvastatin 20 mg | Alirocumab 75 mg/up to 150 mg + Atorvastatin 20 mg | Atorvastatin 80 mg | Rosuvastatin 40 mg | Ezetimibe 10 mg + Atorvastatin 40 mg | Alirocumab 75 mg/up to 150 mg + Atorvastatin 40 mg |
|---|---|---|---|---|---|---|---|
| Percent Change From Baseline in HDL-C at Week 24 - ITT Analysis | 1.9 ± 2.0 | -0.1 ± 2.1 | 4.8 ± 2.0 | 4.7 ± 2.7 | 5.7 ± 2.7 | 2.0 ± 2.7 | 7.7 ± 2.7 |
Adjusted means and standard errors at Week 24 from from a multiple imputation approach model including all available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment.
| percent change | Atorvastatin 40 mg | Ezetimibe 10 mg + Atorvastatin 20 mg | Alirocumab 75 mg/up to 150 mg + Atorvastatin 20 mg | Atorvastatin 80 mg | Rosuvastatin 40 mg | Ezetimibe 10 mg + Atorvastatin 40 mg | Alirocumab 75 mg/up to 150 mg + Atorvastatin 40 mg |
|---|---|---|---|---|---|---|---|
| Percent Change From Baseline in Fasting Triglycerides at Week 24 - ITT Analysis | -6.7 ± 3.7 | -3.3 ± 4.1 | -12.0 ± 3.7 | -7.3 ± 4.1 | -0.5 ± 4.0 | -13.9 ± 4.1 | -19.1 ± 4.10 |
Adjusted LS means and standard errors at Week 24 from MMRM model including all available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment.
| percent change | Atorvastatin 40 mg | Ezetimibe 10 mg + Atorvastatin 20 mg | Alirocumab 75 mg/up to 150 mg + Atorvastatin 20 mg | Atorvastatin 80 mg | Rosuvastatin 40 mg | Ezetimibe 10 mg + Atorvastatin 40 mg | Alirocumab 75 mg/up to 150 mg + Atorvastatin 40 mg |
|---|---|---|---|---|---|---|---|
| Percent Change From Baseline in Apo A-1 at Week 24 - ITT Analysis | 1.2 ± 1.5 | 1.0 ± 1.6 | 7.6 ± 1.5 | 2.2 ± 2.0 | 4.7 ± 1.9 | -1.8 ± 1.9 | 5.8 ± 2.0 |
Adjusted means and standard errors at Week 12 from from a multiple imputation approach model including all available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment.
| percent change | Atorvastatin 40 mg | Ezetimibe 10 mg + Atorvastatin 20 mg | Alirocumab 75 mg/up to 150 mg + Atorvastatin 20 mg | Atorvastatin 80 mg | Rosuvastatin 40 mg | Ezetimibe 10 mg + Atorvastatin 40 mg | Alirocumab 75 mg/up to 150 mg + Atorvastatin 40 mg |
|---|---|---|---|---|---|---|---|
| Percent Change From Baseline in Lipoprotein(a) at Week 12 - ITT Analysis | -11.7 ± 4.0 | -5.4 ± 4.0 | -24.0 ± 4.0 | -1.6 ± 4.5 | 11.5 ± 4.6 | 7.9 ± 4.5 | -27.9 ± 4.5 |
Adjusted LS means and standard errors at Week 12 from MMRM model including all available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment.
| percent change | Atorvastatin 40 mg | Ezetimibe 10 mg + Atorvastatin 20 mg | Alirocumab 75 mg/up to 150 mg + Atorvastatin 20 mg | Atorvastatin 80 mg | Rosuvastatin 40 mg | Ezetimibe 10 mg + Atorvastatin 40 mg | Alirocumab 75 mg/up to 150 mg + Atorvastatin 40 mg |
|---|---|---|---|---|---|---|---|
| Percent Change From Baseline in HDL-C at Week 12 - ITT Analysis | -3.2 ± 1.8 | -1.7 ± 1.8 | 4.1 ± 1.8 | 3.0 ± 2.6 | 4.6 ± 2.7 | 4.6 ± 2.7 | 8.5 ± 2.7 |
Adjusted means and standard errors at Week 12 from from a multiple imputation approach model including all available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment.
| percent change | Atorvastatin 40 mg | Ezetimibe 10 mg + Atorvastatin 20 mg | Alirocumab 75 mg/up to 150 mg + Atorvastatin 20 mg | Atorvastatin 80 mg | Rosuvastatin 40 mg | Ezetimibe 10 mg + Atorvastatin 40 mg | Alirocumab 75 mg/up to 150 mg + Atorvastatin 40 mg |
|---|---|---|---|---|---|---|---|
| Percent Change From Baseline in Fasting Triglycerides at Week 12 - ITT Analysis | -4.7 ± 4.2 | 0.5 ± 4.2 | -12.4 ± 4.2 | -4.6 ± 4.0 | -3.7 ± 4.1 | -16.8 ± 4.0 | -12.1 ± 4.0 |
Adjusted LS means and standard errors at Week 12 from MMRM model including all available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment.
| percent change | Atorvastatin 40 mg | Ezetimibe 10 mg + Atorvastatin 20 mg | Alirocumab 75 mg/up to 150 mg + Atorvastatin 20 mg | Atorvastatin 80 mg | Rosuvastatin 40 mg | Ezetimibe 10 mg + Atorvastatin 40 mg | Alirocumab 75 mg/up to 150 mg + Atorvastatin 40 mg |
|---|---|---|---|---|---|---|---|
| Percent Change From Baseline in Apo A-1 at Week 12 - ITT Analysis | -0.8 ± 1.5 | 1.7 ± 1.4 | 5.4 ± 1.4 | 1.6 ± 1.7 | 5.6 ± 1.7 | 1.6 ± 1.7 | 9.4 ± 1.7 |
Collected over From Baseline up to Week 24. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Atorvastatin 40 mg | — | 2/57 (3.5%) | 17/57 (29.8%) |
| Ezetimibe 10 mg + Atorvastatin 20 mg | — | 5/55 (9.1%) | 24/55 (43.6%) |
| Alirocumab 75 mg/up to 150 mg + Atorvastatin 20 mg | — | 3/57 (5.3%) | 15/57 (26.3%) |
| Atorvastatin 80 mg | — | 4/47 (8.5%) | 18/47 (38.3%) |
| Rosuvastatin 40 mg | — | 2/45 (4.4%) | 23/45 (51.1%) |
| Ezetimibe 10 mg + Atorvastatin 40 mg | — | 2/46 (4.3%) | 12/46 (26.1%) |
| Alirocumab 75 mg/up to 150 mg + Atorvastatin 40 mg | — | 1/47 (2.1%) | 19/47 (40.4%) |
| Event | Atorvastatin 40 mg | Ezetimibe 10 mg + Atorvastatin 20 mg | Alirocumab 75 mg/up to 150 mg + Atorvastatin 20 mg | Atorvastatin 80 mg | Rosuvastatin 40 mg | Ezetimibe 10 mg + Atorvastatin 40 mg | Alirocumab 75 mg/up to 150 mg + Atorvastatin 40 mg |
|---|---|---|---|---|---|---|---|
| Angina unstableCardiac disorders | 0/57 | 0/55 | 2/57 | 0/47 | 0/45 | 0/46 | 0/47 |
| Non-Cardiac chest painGeneral disorders | 0/57 | 0/55 | 0/57 | 0/47 | 1/45 | 0/46 | 0/47 |
| Intraductal proliferative breast lesionNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/57 | 0/55 | 0/57 | 0/47 | 1/45 | 0/46 | 0/47 |
| Coronary artery diseaseCardiac disorders | 0/57 | 0/55 | 0/57 | 0/47 | 0/45 | 1/46 | 0/47 |
| PneumoniaInfections and infestations | 0/57 | 1/55 | 0/57 | 1/47 | 0/45 | 1/46 | 0/47 |
| Atrioventricular block completeCardiac disorders | 0/57 | 0/55 | 0/57 | 1/47 | 0/45 | 0/46 | 0/47 |
| HyperglycaemiaMetabolism and nutrition disorders | 0/57 | 0/55 | 0/57 | 1/47 | 0/45 | 0/46 | 0/47 |
| Chronic obstructive pulmonary diseaseRespiratory, thoracic and mediastinal disorders | 0/57 | 0/55 | 0/57 | 1/47 | 0/45 | 0/46 | 0/47 |
| Aortic aneurysmVascular disorders | 0/57 | 0/55 | 0/57 | 0/47 | 0/45 | 0/46 | 1/47 |
| Cardiac arrestCardiac disorders | 0/57 | 1/55 | 0/57 | 0/47 | 0/45 | 0/46 | 0/47 |
| Event | Atorvastatin 40 mg | Ezetimibe 10 mg + Atorvastatin 20 mg | Alirocumab 75 mg/up to 150 mg + Atorvastatin 20 mg | Atorvastatin 80 mg | Rosuvastatin 40 mg | Ezetimibe 10 mg + Atorvastatin 40 mg | Alirocumab 75 mg/up to 150 mg + Atorvastatin 40 mg |
|---|---|---|---|---|---|---|---|
| Upper respiratory tract infectionInfections and infestations | 2/57 | 4/55 | 2/57 | 2/47 | 3/45 | 5/46 | 3/47 |
| HypertensionVascular disorders | 0/57 | 1/55 | 2/57 | 1/47 | 0/45 | 5/46 | 3/47 |
| NauseaGastrointestinal disorders | 3/57 | 3/55 | 1/57 | 5/47 | 3/45 | 1/46 | 0/47 |
| Urinary tract infectionInfections and infestations | 3/57 | 5/55 | 1/57 | 4/47 | 1/45 | 3/46 | 2/47 |
| NasopharyngitisInfections and infestations | 1/57 | 3/55 | 1/57 | 3/47 | 4/45 | 0/46 | 4/47 |
| Back painMusculoskeletal and connective tissue disorders | 2/57 | 3/55 | 3/57 | 2/47 | 2/45 | 0/46 | 4/47 |
| DiarrhoeaGastrointestinal disorders | 4/57 | 1/55 | 1/57 | 1/47 | 3/45 | 2/46 | 1/47 |
| Muscle spasmsMusculoskeletal and connective tissue disorders | 0/57 | 1/55 | 4/57 | 1/47 | 1/45 | 0/46 | 0/47 |
| InfluenzaInfections and infestations | 1/57 | 1/55 | 1/57 | 0/47 | 3/45 | 0/46 | 2/47 |
| Accidental overdoseInjury, poisoning and procedural complications | 2/57 | 2/55 | 0/57 | 2/47 | 3/45 | 0/46 | 3/47 |
| Age, Continuous(years) | Atorvastatin 40 mg | Ezetimibe 10 mg + Atorvastatin 20 mg | Alirocumab 75 mg/up to 150 mg + Atorvastatin 20 mg | Atorvastatin 80 mg | Rosuvastatin 40 mg | Ezetimibe 10 mg + Atorvastatin 40 mg | Alirocumab 75 mg/ up to 150 mg + Atorvastatin 40 mg | Total |
|---|---|---|---|---|---|---|---|---|
| Mean | 63 ± 9.91 | 65.7 ± 8.96 | 62.2 ± 10.03 | 63.2 ± 10.89 | 57.5 ± 9.96 | 63.9 ± 10.33 | 64.2 ± 10.36 | 62.9 ± 10.2 |
| Sex: Female, Male(Participants) | Atorvastatin 40 mg | Ezetimibe 10 mg + Atorvastatin 20 mg | Alirocumab 75 mg/up to 150 mg + Atorvastatin 20 mg | Atorvastatin 80 mg | Rosuvastatin 40 mg | Ezetimibe 10 mg + Atorvastatin 40 mg | Alirocumab 75 mg/ up to 150 mg + Atorvastatin 40 mg | Total |
|---|---|---|---|---|---|---|---|---|
| Female | 22 | 24 | 24 | 14 | 13 | 11 | 16 | 124 |
| Male | 35 | 31 | 33 | 33 | 32 | 36 | 31 | 231 |
| Low density lipoprotein cholesterol (LDL-C) in mg/dL(mg/dL) | Atorvastatin 40 mg | Ezetimibe 10 mg + Atorvastatin 20 mg | Alirocumab 75 mg/up to 150 mg + Atorvastatin 20 mg | Atorvastatin 80 mg | Rosuvastatin 40 mg | Ezetimibe 10 mg + Atorvastatin 40 mg | Alirocumab 75 mg/ up to 150 mg + Atorvastatin 40 mg | Total |
|---|---|---|---|---|---|---|---|---|
| Mean | 100.3 ± 29.8 | 100.4 ± 29.5 | 103.9 ± 34.9 | 108.6 ± 37.5 | 109.8 ± 39.0 | 98.9 ± 29.2 | 116.4 ± 37.4 | 105.1 ± 34.1 |
| LDL-C in mmol/L(mmol/L) | Atorvastatin 40 mg | Ezetimibe 10 mg + Atorvastatin 20 mg | Alirocumab 75 mg/up to 150 mg + Atorvastatin 20 mg | Atorvastatin 80 mg | Rosuvastatin 40 mg | Ezetimibe 10 mg + Atorvastatin 40 mg | Alirocumab 75 mg/ up to 150 mg + Atorvastatin 40 mg | Total |
|---|---|---|---|---|---|---|---|---|
| Mean | 2.957 ± 0.773 | 2.599 ± 0.765 | 2.692 ± 0.905 | 2.813 ± 0.97 | 2.844 ± 1.011 | 2.562 ± 0.756 | 3.016 ± 0.968 | 2.723 ± 0.884 |
The record gives a start of Oct 2012, a primary completion of Apr 2014 and a completion of May 2014. It does not say whether these dates are actual or estimated.
Results were first posted in Aug 2015, 1 year 4 months after primary completion. A results delay was requested in Jan 2015.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2015. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Alirocumab · Atorvastatin